The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.
Hongyang Lu
No relevant relationships to disclose
Weimin Mao
No relevant relationships to disclose
Qiao-Yuan Cheng
No relevant relationships to disclose
Hai-Miao Xu
No relevant relationships to disclose
Ju-Fen Cai
No relevant relationships to disclose
Xiaojia Wang
No relevant relationships to disclose
CaiJin Lou
No relevant relationships to disclose
Jing Qin
No relevant relationships to disclose
Wei-Wu Ye
No relevant relationships to disclose
Na Han
No relevant relationships to disclose
Lei Lei
No relevant relationships to disclose
Zhiqiang Ling
No relevant relationships to disclose